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Abstract
Epidemiologic studies indicate a strong inverse correlation between plasma levels of high-density lipoproteins
(HDL) and cardiovascular disease (CVD). The most relevant cardioprotective mechanism mediated by HDL is
thought to be reverse cholesterol transport (RCT). New insights in HDL biology and RCT have allowed the
development of promising agents aimed to increase HDL function and promote atherosclerosis regression. In this
regard, apo-AI analogs and CETP inhibitors dalcetrapib and anacetrapib have aroused a great interest and opened
new expectations in the treatment of CVD.
Introduction
Low levels of high-density lipoproteins (HDL) are among
the strongest, statistically independent risk factors for
cardiovascular disease (CVD). It has been estimated that
a 1 mg/dL increase of HDL-cholesterol in plasma results
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accepted mechanism for this HDL protective effect is the
reverse cholesterol transport (RCT). RCT refers to the
mechanism by which cholesterol excess is transported
from cells of extrahepatic tissues and carried back to the
liver, where it can be eliminated or recycled. There has
been a rising interest in the physiology and pharmacology
of RCT [2]. However, contrary to what has been achieved
in the field of LDL control through statin therapy, phar-
macological modulation of HDL biology has not achieved
a comparable success in the clinical arena. Nevertheless,
this growing burden of knowledge has yielded a new gen-
eration of drugs which are under clinical evaluation and
are able not only to increase HDL levels and function,
but also to achieve a measurable atherosclerotic plaque
regression. Within these drugs, apo-AI Milano analogs
and CETP (Cholesterol ester transfer protein) inhibitors
dalcetrapib and anacetrapib deserve to be highlighted
according to the state-of-the-art clinical evidence.
Reverse cholesterol transport (RCT)
Early in the 80’s it was demonstrated that HDL can act as
an acceptor of cellular cholesterol, the first step in the
pathway known as RCT [3]. Briefly, HDL precursors
(lipid-free apoA-I or lipid-poor pre-b1-HDL) are produced
by the liver, the intestine or are released from lipolysed
VLDL and chylomicrons. PLTP (Phospholipid transfer
protein)-mediated phospholipid transfer facilitates apo-AI
lipidation and the formation of pre-b-HDL [2]. Lecithin
cholesterol acyl-transferase (LCAT) esterifies cholesterol
in HDL [4]. Cholesterol esters, more hydrophobic than
free cholesterol, move into the core of HDL particle, creat-
ing a gradient that enables HDL to accept free cholesterol.
After scavenging cholesterol from peripheral tissues, HDL
transports cholesterol to the liver where it will be excreted
or recycled. The selective uptake of cholesterol esters from
HDL into hepatocytes is mediated by the scavenger recep-
tor B type I (SR-BI) [2], and facilitated by the ATP binding
cassette (ABC) transporters ABCA1 and ABCG1 [4].
However, cholesterol esters may also be transferred from
HDL to other lipoproteins, including chylomicrons, VLDL
and LDL, a process mediated by the CETP. Therefore,
CETP possesses a potential atherogenic role by enhancing
the transfer of cholesterol esters from antiatherogenic lipo-
proteins (HDL) to proaterogenic ones (mainly LDL). A
summary of HDL regulation is shown in the Figure 1.
Effects of HDL
Antiatherosclerotic effects of HDL
Atheromatous plaques are not irreversible lesions.
Indeed, pioneer experimental studies have demonstrated
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streaks and induces regression of atherosclerotic lesions
in cholesterol-fed rabbits [5,6]. Nowadays the global
burden of atheromatous plaques can be measured by
novel image techniques. This technology has made it
possible to demonstrate that in animal models athero-
sclerotic plaques are reduced when HDL function is
enhanced [7], and that pharmacologic treatments
that modulate lipid profile (enhance HDL and decrease
LDL) are able to reduce atherosclerosis progression in
humans [8].
Given the central role of HDL in RCT, HDL is con-
sidered essential in therapeutic strategies aimed to inhi-
bit/regress atherosclerotic lesions [2]. HDL can,
therefore, deplete atherosclerotic plaques through their
ability to promote efflux of cholesterol from lipid-loaded
macrophages [9]. However, HDL is a complex macro-
molecule containing diverse bioactive lipids and a
variety of apolipoproteins and enzymes that could indi-
vidually contribute to specific antiatherogenic effects
[10]. These effects are briefly reviewed in the following
sections.
Anti-inflammatory effects of HDL
Numerous studies suggest that the anti-atherogenic
effects of HDL are also related to their anti-inflamma-
tory properties [10,11]. For instance, in macrophages,
HDL prevents the conversion of progranulin into proin-
flammatory granulins [12]; while in endothelial cells,
HDL inhibits the expression of cell adhesion molecules
VCAM-1, ICAM-1 and E-selectin [13,14]. In animal
models, HDL reduces leukocyte homing to arterial
endothelium [15], and increased HDL levels have been
associated with a decrease of the blood concentration of
proinflammatory molecules both in animal models and
in patients [16,17].
Figure 1 Simplified scheme of reverse cholesterol transport. In the onset and progression of atherosclerotic lesions the uptake of modified
LDL (mainly oxidized LDL or oxLDL) by macrophages through a process mediated by scavenger receptors (i.e. SR-A and CD36) that lead to the
formation of lipid-loaded cells is critical. This seems to be a reversible process, as HDL-mediated RCT can clear cholesterol from vascular tissues
contributing to atherosclerosis regression. HDL acquires cholesterol through a mechanism that involves the receptor SR-BI and transports this
cholesterol back to the liver. However, HDL also exchanges lipids with LDL, a process mediated by the CETP that increases LDL cholesterol cargo
and potentially enhances their atherogenicity.
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HDL lipoproteins are able to counteract LDL oxidation,
which is commonly considered a key event in atherogen-
esis. HDL inhibits the enzymatic and non-enzimatic oxi-
dation of LDL, and exerts indirect antioxidant effects
acting as a “sink” for oxidized products that come from
oxidized LDL and transport them to the liver [18]. The
antioxidant properties of HDL are attributed not only to
apoA-I, the most abundant protein in HDL, but also to
several enzymes including paraoxonase (PON), platelet-
activating factor acetylhydrolase (PAF-AH) and glutation
peroxidase (GPx) [19].
Antithrombotic effect of HDL
Deregulation of haemostasis plays a key role in acute cor-
onary syndromes. Tissue factor activates the extrinsic
coagulation pathway and is essential in atheromatous pla-
que rupture. HDL is able to reduce thrombin-induced
tissue factor expression in endothelial cells [20], to inhibit
platelet activation [21], and to stimulate the activation of
the anticoagulant proteins C and S [22].
HDL increases the release of two major antiathero-
genic/antithrombotic molecules by vascular cells: nitric
oxide (NO) and prostacyclin [23]. HDL not only prevents
the inhibition of endothelial nitric oxide synthase (eNOS)
by oxLDL [24], but also induces per se eNOS [25] leading
to the increase in NO production by the endothelium.
Emerging strategies to increase HDL: apo-AI
Milano and CETP inhibition
Genetics of HDL: apo-AI Milano
Apo-AI Milano is a naturally occurring mutant of apo-AI
first described in 1980 [26]. Paradoxically, carriers of this
mutation have very low HDL cholesterol levels, but no
increase in the risk of heart disease. In apo-AI Milano
arginine in position 173 has been substituted by cysteine.
This extra cysteine confers the capacity to form disulfide
bonds yielding homodimers and heterodimers with apo-
AI [27]. Several studies in rabbits that received recombi-
nant apo-AI Milano suggest that apo-AI Milano could
increase RCT [28], although this has not been observed in
mice expressing apo-AI Milano [29].
CETP and cholesterol efflux to the liver
CETP is synthesized in the liver, spleen, adipose tissue and
macrophages, and circulates in plasma bound to HDL.
The main function of CETP is to facilitate the transport of
cholesterol esters and triglycerides among lipoproteins [2].
It collects cholesterol esters from HDL and exchanges
them for triglycerides from chylomicrons, VLDL and LDL,
and viceversa (Figure 1). Therefore, the net effect of CETP
is proatherogenic. In fact, rare mutations leading to
increased function of CETP have been linked to promote
CVD [30]. On the other hand, genetic deficiency of CETP
leads to marked increase in plasma levels of large HDL
particles, and these HDL have enhanced ability to promote
cholesterol efflux from foam cells [31]. CETP activity is
also inhibited by current lipid-lowering drugs, such as
statins, fibrates and niacin [32]. Thus, this molecule may
be considered as an interesting therapeutical target in
order to prevent cardiovascular disease. However, recent
epidemiological studies seem to challenge the mainstream
consideration of CETP as a proatherogenic stimulus. In
two different large population-based studies, CETP muta-
tion has been associated with greater risk of cardiovascular
disease [33,34].
Emerging drugs to increase HDL function
Apo-AI mimetics
When combined with phospholipids, recombinant apo-AI
Milano (ETC-216) can be given in an intravenous setting.
It has been shown to decrease atherosclerotic plaque size
in animal models [7]. This effect has also been demon-
strated in humans [35]. After five weeks of this intrave-
nous treatment with ETC-216, patients have an increase
of HDL, a remarkable decrease of atheromatous burden
and a subsequent lower cardiovascular morbimortality
[36,37]. In some of these analogs, four phenylalanine resi-
dues make a gastro-resistant molecule which enables its
oral administration [38]. Notably, considerable debate still
exists whether injection of wild-type Apo-AI can be as
effective as this natural variant to stimulate RCT [39-41].
A brief summary on the clinical evidence of infusion of
apo-AI Milano and wild-type apo-AI is shown in the
Table 1.
CETP inhibition
Some CETP inhibitors have been demonstrated to possess
a significant effect to increase HDL and decrease LDL
(Figure 2). Torcetrapib showed an important effect in the
rise of HDL in animal models and in the clinical arena.
Among phase III studies, the ILLUSTRATE trial (910
patients, double-blind, randomized trial) compared torce-
trapib and atorvastatin against atorvastatin alone [42]. It
showed that in the highest quartile of HDL increase, a
higher atherosclerotic regression measured by ultrasound
was observed [42]. However, no benefit was observed in
the whole cohort, and a higher rate of high blood pressure
was noted in the torcetrapib group [42]. This torcetrapib-
linked adverse effect was confirmed in the double-blind,
randomized, ILLUMINATE trial (15067 patients, same
comparative groups). In this trial, a higher overall cardio-
vascular mortality was noted in the torcetrapib group
despite an efficient HDL increase [43]. This was related to
sodium rise, potassium decrease and blood pressure
increase, and therefore the study was stopped, the drug
being withdrawn in the United States and the European
Union [44]. Further studies linked these effects with a
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Study Patients Administration Result
Nicholls et al.,
[36]
47 post-acute coronary events (randomized) Intravenous
Apo-AI Milano
4.6% decrease of lamina elastic interna (measured by ultrasound)
Nissen et al.,
[37]
123 post-acute coronary events (randomized) Intravenous
Apo-AI Milano
4.2% decrease of atheromatous plaque volume (measured by ultrasound)
Tardif et al.,
[40]
183 patients on coronariography (randomized) Intravenous
reconstituted wild-type HDL










































































































8torcetrapib-mediated increase in mineralocorticoid stimu-
lation [45]. However, this effect is not mediated by CETP
inhibition and therefore is not necessarily shared by other
CETP blockers. Therefore, the role of CETP inhibitors dal-
cetrapib [46] and anacetrapib [47] is being evaluated, given
that they seem to increase HDL without the adverse effect
in blood pressure. Ongoing big phase III will eventually
show the potential of these promising drugs.
Dalcetrapib (Figure 2) offers the advantage of a high
pharmacological potency, having 0.4-10 μMI C 50 for the
inhibition of CETP (compared to 19-79 μM of torcetra-
pib). Dalcetrapib is highly specific for the interaction of
cysteine 13 from CETP [32]. Preclinical animal models
showed its capability to increase HDL without a significant
increase in blood pressure [48]. Further clinical trials
demonstrated that it does not possess hypertensive effect
in humans and strengthened the idea that dalcetrapib rises
HDL without any significant increase in blood pressure
[46,49]. Large phase III trials are still ongoing with this
drug. The dal-VESSEL trial will assess the effect of dalce-
trapib in the reduction of atheromatous plaques measured
by PET/TAC and MRI [32]. The dal-OUTCOMES trial
will evaluate the effect of the drug on the cardiovascular
morbimortality of a sample of 15600 high-risk patients
[32].
Anacetrapib (Figure 2) is another CETP inhibitor. It has
an IC50 of 15-57 μM [32]. Its capability to raise HDL with-
out a parallel increase of blood pressure has been demon-
strated in phase I trials [50]. A broader study (589
patients) showed that treatment of anacetrapib and ator-
vastatin 20 mg increased HDL [51]. Anacetrapib, at the
maximum tolerated dose of 300 mg, is able to increase
HDL and decrease LDL. However, this last effect is nota-
bly enhanced when given with statins, reaching a 70%
reduction, without any increase in blood pressure [51].
Based on this synergism strategy, the DEFINE trial will
Figure 2 Chemical structure of torcetrapib, dalcetrapib and anacetrapib.
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Page 5 of 8evaluate the role of anacetrapib on 1623 patients whose
statin treatment has achieved LDL < 100 mg/dl, but hav-
ing HDL < 60 mg/dl [32].
Liver × Receptor (LXR) agonists
There are two LXR isoforms: LXRb, ubiquitously
expressed, and LXRa distributed in a tissue-specific fash-
ion, but mainly in liver and tissues involved in lipid meta-
bolism. LXRs are activated by specific oxidized forms of
cholesterol (oxysterols) such as 24(S)-hydroxycholesterol
and by certain intermediates of the cholesterol biosynth-
esis. Analysis of LXR-deficient mice has revealed a broad
role of this receptor in the regulation of genes involved
in lipid homeostasis [52]. For instance, in mice LXR ago-
nists reduce cholesterol absorption in the intestine due to
the up-regulation of ABCG5 and ABCG8, which increase
the efflux of cholesterol thereby limiting its absoption by
intestinal cells [53]. Most interestingly, ABCA1, a key
transporter in the efflux of cholesterol and phospholipids
from macrophages, is a direct target of LXR [54]. In fact,
treatment with endogenous LXR agonists is able to
increase the RCT from macrophages and foam cells and
thus increase the biliary excretion of this lipid [55]. At
the same time, synthetic LXR agonists are able to prevent
atheromatous plaque formation in mice [56]. However,
these drugs promote the expression of lipogenic genes in
the liver, which increase the levels of triglycerides and
promote hepatic steatosis [57]. For this reason, research
on more selective LXR ligands is an active field of experi-
mental pharmacology.
Scavenger receptor B-1 (SR-BI) inhibitors
SR-BI is a receptor which modulates the hepatic uptake
of cholesterol esters by HDL, VLDL and native LDL.
Mice without SR-BI have increased LDL levels and are
prone to atherosclerosis [58]. However, in humans SR-
BI blockade by ITX5061, a molecule initially character-
ized as a p38 mitogen-activated protein kinase (MAPK)
inhibitor, increases HDL, although this effect seems to
be very transient [59].
Summary
RCT is thought to be one of the most important HDL-
mediated cardioprotective mechanisms. However, con-
trary to what has been achieved with LDL modulation by
statin treatment, this mechanism has not been able to be
modulated by safe and effective drugs to date. In fact, the
beneficial therapeutic effects of raising HDL are proving
difficult to confirm in humans. Recent experimental,
translational and clinical research has yielded new drugs
inspired, in some cases, in variants found in Nature, such
as apo-AI Milano analogs, and CETP inhibitors (dalcetra-
pib and anacetrapib). Low HDL level is the most frequent
lipoprotein abnormality in patients suffering premature
CVD. In this context, ongoing clinical studies with emer-
ging drugs aimed to increase HDL function have aroused
a great interest and opened new expectations in the treat-
ment of CVD.
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